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Impact of Time to Appropriate Therapy on Mortality in Patients with
Vancomycin-Intermediate Staphylococcus aureus Infection
Jason P. Burnham,a Carey-Ann D. Burnham,b David K. Warren,a Marin H. Kollefc
Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USAa; Department of Pathology & Immunology, Washington University
School of Medicine, St. Louis, Missouri, USAb; Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USAc
Despite the increasing incidence of vancomycin-intermediate Staphylococcus aureus (VISA) infections, few studies have exam-
ined the impact of delay in receipt of appropriate antimicrobial therapy on outcomes in VISA patients. We examined the effects
of timing of appropriate antimicrobial therapy in a cohort of patients with sterile-site methicillin-resistant S. aureus (MRSA)
and VISA infections. In this single-center, retrospective cohort study, we identified all patients withMRSA or VISA sterile-site
infections from June 2009 to February 2015. Clinical outcomes were compared according toMRSA/VISA classification, demo-
graphics, comorbidities, and antimicrobial treatment. Thirty-day all-cause mortality was modeled with Kaplan-Meier curves.
Multivariate logistic regression analysis (MVLRA) was used to determine odds ratios for mortality. We identified 354 patients
withMRSA (n 267) or VISA (n 87) sterile-site infection. Fifty-five patients (15.5%) were nonsurvivors. Factors associated
with mortality in MVLRA included pneumonia, unknown source of infection, acute physiology and chronic health evaluation
(APACHE) II score, solid-organmalignancy, and admission from skilled care facilities. Time to appropriate antimicrobial ther-
apy was not significantly associated with outcome. Presence of a VISA infection compared to that of a non-VISA S. aureus infec-
tion did not result in excess mortality. Linezolid use was a risk for mortality in patients with APACHE II scores of>14. Our re-
sults suggest that empirical vancomycin use in patients with VISA infections does not result in excess mortality. Future studies
should (i) include larger numbers of patients with VISA infections to confirm the findings presented here and (ii) determine the
optimal antibiotic therapy for critically ill patients withMRSA and VISA infections.
Broad-spectrum antimicrobial coverage for patients with se-vere infections followed by de-escalation when culture data
are available is now a standard of care (1). Vancomycin has his-
torically been the empirical therapy of choice for coverage of
possible methicillin-resistant Staphylococcus aureus (MRSA)
infection. The emergence of vancomycin-intermediate S. aureus
(VISA) infections (vancomycin MIC of 4 or 8 g/ml) threatens
the efficacy of vancomycin as empirical therapy in the manage-
ment of critically ill patients (2–5). Delays in appropriate antimi-
crobial treatment of greater than 24 h in patients with MRSA
sterile-site infections are known to increase mortality (6). Despite
the increasing incidence of VISA infections (7) in a population
that still predominantly receives vancomycin as the first-line em-
pirical therapy for MRSA, no studies have specifically examined
the impact of delay in receipt of appropriate antimicrobial therapy
on outcomes in VISA patients. The primary objective of our study
was to determine risk factors for mortality in patients with MRSA
(non-VISA) and VISA sterile-site infections, particularly whether
time to appropriate antimicrobial therapy was associated with
mortality. Our secondary objectives were to (i) determine predic-
tors of VISA infection and (ii) determine the impact of definitive
MRSA or methicillin-resistant, vancomycin-intermediate S. au-
reus (MRVISA) therapy on outcome.
MATERIALS AND METHODS
Study location and patient population. This study was conducted at
Barnes-Jewish Hospital, a 1,250-bed academic medical center located in
St. Louis, MO. The study period was June 2009 through February 2015,
corresponding to the change of vancomycinMIC by Clinical and Labora-
tory Standards Institute (CLSI) in 2006 and the subsequent adoption of a
screening agar in 2009 for detection of the vancomycin-intermediate phe-
notype in S. aureus isolates recovered from clinical specimens as previ-
ously described (8). Briefly, S. aureus isolates recovered from all blood
cultures are inoculated onto brain heart infusion agar with 3 mg/liter
vancomycin (BHI-V3) and the vancomycin MIC of any S. aureus isolates
that growon this agar is confirmed (the confirmatorymethodology varied
during the study period but included Microscan, Etest, and Vitek2) (8).
All consecutive hospitalized patients with MRSA or VISA cultures from
sterile sites were analyzed for eligibility. This study was approved by the
Washington University School of Medicine Human Studies Committee.
Study design and data collection. Utilizing a retrospective cohort
study design, all patients 18 years of age with MRSA or VISA cultured
from sterile sites were identified. Sterile sites were defined as blood, cere-
brospinal fluid (CSF), pleural fluid (not taken from indwelling catheter),
ascites fluid (not taken from indwelling catheter), pericardial fluid, bone
marrow, and synovial fluid and surgical specimens from lymph nodes,
brain, heart, liver, spleen, vitreous, kidney, pancreas, ovary, or vascular
tissue. Patients with sterile sites which grew MRSA or VISA as part of a
polymicrobial culture were excluded from the study. All vancomycin ex-
posures within our health care systemwithin 6months of the first positive
culture were considered. Receipt of vasopressors within 24 h of positive
culture was used to define septic shock. The primary endpoint was 30-day
all-cause mortality in the MRSA and VISA groups, with special attention
to the timing of appropriate therapy. Secondary endpoints included hos-
pital length of stay (LOS) and intensive care unit length of stay (ICU LOS)
postinfection, effect of definitive antibiotic on mortality, predictors of
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VISA infection, and duration of prior vancomycin exposure. Baseline
characteristics, including age, gender, race, place of origin, health care
exposure, receipt of vancomycin within 6 months of positive culture,
presence of immunosuppression, acute physiology and chronic health
evaluation (APACHE) II (9) scores (calculated based on clinical data pres-
ent during the 24 h after positive blood cultures were drawn), Charlson
comorbidity index, and medical comorbidities, were obtained.
Definitions. Patients were considered to have a VISA infection if S.
aureus was isolated in culture and was determined to have a vancomycin
MIC of 4 or 8 g/ml, in accordance with CLSI standards (10).
Time to appropriate therapy was calculated from the time a positive
blood culture was drawn to the time that the first appropriate antibiotic
was administered. All isolates had to have test results showing that they
were susceptible to the antibiotic in order for therapy to be considered
appropriate. The definition of appropriate therapy was different for each
subcategorization. For MRSA, appropriate therapy was defined as the
receipt of linezolid, ceftaroline, daptomycin, telavancin, quinupristin-
dalfopristin, or vancomycin. In patients with MRVISA, appropriate ther-
apy was defined as the receipt of any of the antibiotics listed above for
treatment of MRSA infection, with the exclusion of vancomycin. For pa-
tients withMSVISA, appropriate therapy was defined as the receipt of any
of the antibiotics considered appropriate for MRVISA, with the addition
of cefazolin, ceftriaxone, oxacillin, nafcillin, and dicloxacillin. For all
subcategorizations to include MSVISA and MRVISA, in order for any
antibiotic to be considered appropriate therapy, isolates had to test as
susceptible to that antibiotic in accordance with CLSI standards (10).
Additionally, daptomycin was not considered appropriate for patients
with pulmonary infections. Definitive therapy was defined as the appro-
priate antibiotic therapy (see above) that patients received for themajority
(50%) of their treatment course.
Vancomycin trough levels were not available for all patients. It is in-
stitutional policy to administer vancomycin at a dose of 15mg/kg of body
weight, with a dosing interval appropriate for the patient’s creatinine
clearance. Target trough levels for all patients were 15 to 20 mg/dl. Insti-
tutional policy is to dose daptomycin for all S. aureus infections at 6mg/kg
of ideal body weight, 6 mg/kg of adjusted body weight if the BMI of the
patient is120% of the ideal BMI, and 6 mg/kg of total body weight for
underweight patients. This dosing of daptomycin also applied to VISA
infections.
Patients were identified by the first sterile site from which MRSA or
VISAwas isolated. Patients could be included in the studymore than once
only if a S. aureus infection occurred during a different hospitalization
more than 30 days after completing a treatment course for a previous S.
aureus infection.
Wedefined the septic shock group as receipt of blood pressure support
with any of the following medications within 24 h of the first positive
culture: norepinephrine, phenylephrine, epinephrine, dopamine, dobut-
amine, or vasopressin.
The following organismswere considered contaminants if not isolated
in more than one blood culture within 72 h: coagulase-negative staphylo-
cocci, Corynebacterium spp., Propionibacterium acnes, or viridans group
Streptococcus. Length of hospital stay postinfection was calculated from
the time a positive sterile-site culture was drawn. Patients who never re-
quired intensive care unit (ICU) admission were considered to have an
ICU stay length of 0 days. Health care exposure was defined as chemo-
therapy within the prior 30 days; residence in a nursing home (NH),
skilled-nursing facility (SNF), or other long-term acute-care facility
(LTACH); hospitalization in an acute care hospital for two or more days
within the prior 90 days; or attendance at a hospital or hemodialysis clinic
within the prior 30 days.
Immunosuppression was defined as receipt of any of the following
drugs within 30 days: glucocorticoids (20 mg prednisone equivalents/
day for 3 months), cyclosporine, tacrolimus, sirolimus, temsirolimus,
everolimus, mycophenolate mofetil, methotrexate, azathioprine, 6-mer-
captopurine, cyclophosphamide, gold, D-penicillamine, sulfasalazine, an-
tithymocyte globulin, rituximab, ofatumumab, muromonab, alemtu-
zumab, basiliximab, daclizumab, tocilizumab, belimumab, abatacept,
belatacept, natalizumab, efalizumab, fingolimod, infliximab, adali-
mumab, certolizumab pegol, etanercept, golimumab, eculizumab,
leflunomide, anakinra, adalimumab, auranofin, and any intravenous
(i.v.) chemotherapeutic agents used in the treatment of malignancy.
Thirty-day mortality was assessed using the informatics database of
BJC HealthCare, a large integrated health care system of both inpatient
and outpatient care. Barnes-Jewish Hospital serves as the main teaching
institution for BJCHealthCare. The system includes a total of 13 hospitals
in a compact geographic region surrounding and including St. Louis,MO.
Persons treated within this health care system are, in themajority of cases,
readmitted to one of the system’s participating hospitals or evaluated in a
BJC HealthCare outpatient practice. If a patient who receives health care
in the system presents to a nonsystem hospital, he/she is often transferred
back into the integrated system because of issues of insurance coverage.
Death certificate records and autopsy reports are included in the infor-
matics database. All data were derived from the informatics database pro-
vided by the Center for Clinical Excellence, BJC HealthCare.
Statistical analysis. Thirty-day all-cause mortality was modeled with
Kaplan-Meier curves. Univariate analysis was performed by chi-square or
Fisher’s exact test where appropriate for categorical values. Student’s t test
or the Mann-Whitney U test was performed where appropriate for con-
tinuous variables. Continuous variables are reported as means with stan-
dard deviations. Categorical data are expressed as frequencies. AP value of
0.05 was considered significant. Factors associated with VISA infection
in univariate analysis (P 0.20) were entered into a multivariate logistic
regression analysis (MVLRA) to determine odds ratios (ORs) for VISA
infection. Factors associated with 30-day all-cause mortality in univariate
analysis (P 0.20) were subjected to non-stepwise MVLRA to determine
odds ratios for death. All variables entered into the model were assessed
for colinearity, and interaction terms were tested. Goodness of fit was
assessed via the Hosmer-Lemeshow c-statistic method. All analyses were
performed using SPSS v22. A 2-tailed P value of 0.05 was considered
significant in all statistical tests.
We also planned to perform two sensitivity analyses of the cohort: one
analysis limited to patients with APACHE II scores of14 and one which
excluded patients with infections due to central venous catheters.
RESULTS
Study cohort. Following initial data collection, 362 patients met
the inclusion criteria; among those patients, 8 were ultimately
excluded (Fig. 1). Two patients on inappropriate antibiotics were
discharged but were still included, as one patient was put on ap-
propriate therapy as an outpatient and the other patient was read-
mitted for appropriate therapy. Two patients, both with MSVISA
infections, died before receiving appropriate antibiotics; for these
patients, the time to appropriate therapy was calculated as the
time to death. Our final cohort consisted of 354 patients, 342
(96.6%) of whom had 1 positive blood culture(s). Six patients
had negative blood cultures, and six patients had no blood cul-
tures performed.
MRSA versus VISA. A total of 267 MRSA (non-VISA) and a
total of 87 VISA (68% MRSA, 32% MSSA) sterile-site infections
met the inclusion criteria. Baseline characteristics of the patients
are listed in Table 1. In univariate analysis, solid-organ malig-
nancy, cirrhosis, APACHE II, origin NH/SNF/LTACH, hemodi-
alysis (HD) or arteriovenous (AV) graft, pneumonia, and discitis/
osteomyelitis data had P values of0.20 in comparisons ofMRSA
patients to VISA patients. Time to appropriate antibiotics was
significantly longer in the VISA group in univariate analysis (Ta-
ble 1). Among patients who received any vancomycin, there was
no significant difference betweenMRSA (n 229) andVISA (n
Time to Appropriate Therapy
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68) patients in the starting dose (Table 1). Surprisingly, there was
no significant difference between the MRSA and VISA groups in
total duration of antecedent vancomycin exposure within 6
months (Table 1). The percentage ofMRSA patients who had had
any vancomycin exposure within the prior 6 months was 35.2
(n  94), and the percentage of VISA patients who had had any
vancomycin exposure within the prior 6 months was 35.6 (n 
31). Analyzed at 1 day, 7 days, 2 weeks, 4 weeks, and 6 weeks of
prior vancomycin exposure, there was still no significant differ-
ence between theMRSA andVISA groups in duration of exposure
in analyses performed at the level of the whole cohort, nor when
analyzed only amongst those that had any prior vancomycin ex-
posure. Themajority ofMRSA andVISApatients (64.9% [n 61]
and 74.2% [n  23], respectively) had less than 7 days of prior
vancomycin exposure. Under half, 33.0% (n 31) forMRSA and
48.4% (n 15) for VISA, had less than 72 h of vancomycin expo-
sure. Inmultivariate analysis, no factors were significantly predic-
tive of VISA infection.
Survivors versus nonsurvivors. At 30 days, there were 299
survivors and 55 nonsurvivors. Data corresponding to increased
age, presence of shock, cardiovascular disease, solid-organ malig-
nancy, APACHE II, Charlson comorbidity index, origin from a
NH, SNF, or LTACH, origin from the community, unknown
source of infection, pneumonia as infection source, and treatment
with linezolid were significantly different between survivors and
nonsurvivors in univariate analysis (Table 1). Time to appropriate
antibiotic therapy had no effect on mortality, as assessed in
MVLRA. There was no significant difference between survivors
and nonsurvivors in time to appropriate therapy analyzed at the
level of the whole cohort or byMRSA/VISA classification (Fig. 2).
Among patients who received any vancomycin, there was no sig-
nificant difference in the starting dose between survivors (n 
250) and nonsurvivors (n 47) patients (Table 1). Inmultivariate
analysis, patients who died were more likely to have had higher
APACHE II scores, pneumonia or an unknown infection source,
or a solid-organmalignancy or to have been admitted from aNH,
SNF, or LTACH (Table 2). An attempt was made to incorporate
the presence of VISA into the MVLRA data for mortality, but this
did not significantly affect the model’s performance.
On Kaplan-Meier analysis, there was no difference in 30-day
all-cause mortality between patients with MRSA (non-VISA) and
those with VISA (Fig. 3). Data corresponding to the definitive
therapy for MRVISA patients are shown in Table 3. All VISA iso-
lates had a vancomycinMIC of 4g/ml. Table 4 shows the results
of our sensitivity analyses in patients with an APACHE II score of
14 and in all patients with non-central venous catheter infec-
tions.
DISCUSSION
The mortality rate in our cohort (15.5%) was similar to that seen
in prior studies of S. aureus infections of sterile body sites. We
found that the time to appropriate antibiotic therapy was not a
predictor of 30-day all-cause mortality. This finding held true for
analysis of that parameter as a dichotomous variable at cutoffs of
1, 6, 12, 24, and 48 h (data not shown). Time to appropriate ther-
apy was almost 2 days longer in patients with VISA infections,
without an increased risk of mortality. To our knowledge, no
studies have been performed that specifically examined time to
appropriate therapy as a risk factor for mortality in patients with
VISA. Even among studies that have compared outcomes of infec-
tions by MRSA with reduced vancomycin susceptibility, cutoffs
for reduced vancomycinMICs have been variable. Some studies in
patients with MRSA infection have found an increased risk of
mortality when appropriate therapy was delayed for more than 2
days, thoughwith disparate conclusions regarding the role of van-
comycin MIC in outcomes (11, 12).
One possible explanation for the lack of increased mortality in
the VISA group in our cohort despite a 48-h delay in appropriate
antibiotic therapy relative to the MRSA group is that vancomycin
resistance comes with a fitness cost, as has been suggested previ-
ously (13, 14). Another possible explanation is that we are wit-
nessing a “90–60 rule” (15) effect in patients with VISA who
are treated with vancomycin; vancomycin usage may not cure the
infection all the time but does at least decrease the risk ofmortality
FIG 1 Study cohort exclusion flowchart. MRSA, methicillin-resistant Staphylococcus aureus; MRVISA, methicillin-resistant vancomycin-intermediate Staphy-
lococcus aureus; MSVISA, methicillin-susceptible vancomycin-intermediate Staphylococcus aureus; VISA, vancomycin-intermediate Staphylococcus aureus.
Burnham et al.
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(30 days) (n 55) P value
Age (yr) 56.8 16.7 55.3 16.3 0.479 55.3 16.2 62.4 17.4 0.003
Male sex 59.9 (160) 64.4 (56) 0.461 61.9 (185) 56.4 (31) 0.441
White ethnicity 63.3 (169) 60.9 (53) 0.691 61.2 (183) 70.9 (39) 0.171
Use of vasopressors 31.5 (84) 28.7 (25) 0.633 26.1 (78) 56.4 (31) 0.001
Bone marrow transplant 3.7 (10) 2.3 (2) 0.738 3.0 (9) 5.5 (3) 0.409
Solid-organ transplant 4.9 (13) 1.1 (1) 0.202 3.7 (11) 5.5 (3) 0.464
Cardiovascular disease 34.8 (93) 31.0 (27) 0.516 31.1 (93) 49.1 (27) 0.010
Congestive heart failure 31.8 (85) 27.6 (24) 0.456 29.1 (87) 40.0 (22) 0.107
Chronic respiratory failure 24.3 (65) 27.6 (24) 0.545 25.1 (75) 25.5 (14) 0.954
Diabetes mellitus, type 2 36.7 (98) 33.3 (29) 0.569 36.1 (108) 34.5 (19) 0.823
CKD/RRT 34.5 (92) 36.8 (32) 0.693 34.4 (103) 38.2 (21) 0.594
Solid-organ malignancy 13.1 (35) 19.5 (17) 0.141 12.4 (37) 27.3 (15) 0.004
Leukemia 8.2 (22) 8.0 (7) 0.954 8.4 (25) 7.3 (4) 1
Lymphoma 2.2 (6) 2.3 (2) 0.978 1.7 (5) 5.5 (3) 0.112
Cirrhosis 2.6 (7) 6.9 (6) 0.066 2.7 (8) 9.1 (5) 0.036
Health care exposure 83.9 (224) 83.9 (73) 0.998 82.3 (246) 92.7 (51) 0.070
Time to appropriate antibiotics (days) 0.23 [0.0, 0.70] 2.55 [0.65, 3.77] 0.001 0.40 [0.0, 1.34] 0.40 [0.7, 1.04] 0.918
Immunosuppression 18.7 (50) 19.5 (17) 0.866 19.1 (57) 18.2 (10) 0.878
Charlson comorbidity score 3.7 3.0 3.5 2.9 0.493 3.4 2.8 5.0 3.5 0.001
APACHE II score 14.1 5.6 13.1 4.8 0.172 13.1 5.1 17.8 5.8 0.001
Patient origin, % (n)
NH, SNF, or LTACH 13.5 (36) 5.7 (5) 0.054 10.0 (30) 20.0 (11) 0.034
Community 44.9 (120) 40.2 (35) 0.441 46.5 (139) 29.1 (16) 0.017
OSH 24.3 (65) 31.0 (27) 0.216 26.4 (79) 23.6 (13) 0.665
In hospital 16.1 (43) 20.7 (18) 0.325 15.7 (47) 25.5 (14) 0.079
Infection source, % (n)
Endocarditis 11.6 (31) 11.5 (10) 0.977 11.7 (35) 10.9 (6) 0.865
Hemodialysis graft or AV fistula 2.6 (7) 5.7 (5) 0.177 3.7 (11) 1.8 (1) 0.700
Central venous catheter 18.7 (50) 19.5 (17) 0.866 20.4 (61) 10.9 (6) 0.098
Unknown 27.3 (73) 33.3 (29) 0.284 25.1 (75) 49.1 (27) 0.001
Pneumonia/empyema 7.9 (21) 2.3 (2) 0.080 4.3 (13) 18.2 (10) 0.001
Discitis/osteomyelitis 14.2 (38) 6.9 (6) 0.072 13.7 (41) 5.5 (3) 0.117
Septic arthritis 3.7 (10) 4.6 (4) 0.753 4.7 (14) 0 0.139
Skin and soft tissue infection 5.6 (15) 5.7 (5) 1 4.7 (14) 0 0.139
Otherb Not significant Not significant
Initial vancomycin dose (g)c 1,143 331 1,198 316 0.222 1,163 331 1,117 316 0.380
Total prior vancomycin exposure, days 0 [0.0, 2.79] 0 [0.0, 1.85] 0.612 0 [0.0, 1.96] 0 [0.0, 2.97] 0.123
LOS (days) 12.0 [7, 13] 10.0 [7, 21] 0.598 11 [7, 23] 12 [6, 19] 0.200
ICU LOS (h) 0 [0.0, 146.3] 0 [0.0, 149.7] 0.487 0 [0.0, 116.65] 97.6 [32.7, 288.5] 0.001
30-day all-cause mortality, % 16.9 11.5 0.231
MRSA 74.2 (222) 81.8 (45) 0.231
MRVISA 17.7 (53) 10.9 (6) 0.213
MSVISA 8.0 (24) 7.3 (4) 1
Any VISA 25.8 (77) 18.2 (10) 0.231
Vancomycin treated 41.8 (125) 43.6 (24) 0.801
Linezolid treated 10.0 (30) 23.6 (13) 0.005
a Values are expressed as means  standard deviations, percentages (numbers of patients), or medians [interquartile ranges]. For the MRSA and VISA groups, the origins
of 3 and 2 patients, respectively, could not be definitively determined based on chart review. The origins of 4 survivors and 1 nonsurvivors could not be determined.
Abbreviations: CKD, chronic kidney disease; RRT, renal replacement therapy; APACHE II, acute physiology and chronic health evaluation II; NH, nursing home; SNF,
skilled-nursing facility; LTACH, long-term acute-care hospital; OSH, outside hospital; LVAD, left ventricular assist device; AICD, automatic implantable cardioverter
defibrillators; PPM, permanent pacemaker; LOS, length of stay; ICU LOS, intensive care unit length of stay; MRSA, methicillin-resistant Staphylococcus aureus; MRVISA,
methicillin-resistant vancomycin-intermediate Staphylococcus aureus; MSVISA, methicillin-susceptible vancomycin-intermediate Staphylococcus aureus; VISA, vancomycin-
intermediate Staphylococcus aureus.
b Data include the following types of infections: surgical site, LVAD, prosthetic joint, traumatic wound, thrombophlebitis, urine, AICD/PPM, endovascular graft. None of these
categorizations were significantly different between groups. Each of these infection types had8 infections in any column (MRSA, VISA, survivors, or nonsurvivors).
c A total of 229 MRSA patients, 68 VISA patients, 250 survivors, and 47 nonsurvivors received vancomycin.
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while the patient is awaiting appropriate definitive therapy. Fur-
ther studies need to be conducted to assess this possibility. If true,
it wouldmean that vancomycin can remain an empirical first-line
therapy for MRSA without risking adverse outcomes. It would
also reduce the need to empirically prescribe nonvancomycin
MRSA therapy in patients with a history of VISA infection when
they are readmitted with concern for infection. It should be noted
that the risk of readmission with VISA after an initial VISA infec-
tion is not known.Of the 87VISApatients in our cohort, 41 (47%)
were readmitted within 120 days of discharge from the date of
VISA admission; only 3, all of whom had VISA infections, had a
recurrent S. aureus infection.
The impact on mortality of an infection by a VISA or S. aureus
strain with a phenotype of heterogeneous resistance to vancomy-
cin (hVISA) is unclear, as there is significant heterogeneity of re-
sults and study designs in the literature. Evidence can be found to
suggest that VISA infection results in reduced, similar, or in-
creased mortality relative toMRSA orMSSA infection (2, 16–19).
Even several recent meta-analyses came to differing conclusions;
three studies associated elevated vancomycin MICs with an in-
creased risk of mortality, though with different MIC cutoffs in
each study (20–22), and a fourthmeta-analysis found no evidence
of increased mortality risk based on vancomycin MIC (23).
Pneumonia, unknown infection source, APACHE II score, or-
igin from a NH, SNF, or LTACH, and solid-organ malignancy
have all been shown previously to be risk factors for mortality in
patients with S. aureus. It is not surprising that these factors, which
are likely all surrogates for severity of illness, were associated with
increased risk of mortality.
Few studies have specifically examined exposure rates and dif-
ferences in duration of prior vancomycin administration in VISA
and MRSA patients, though what data are available suggest that
about 25% of patients with MRSA infections have had prior van-
comycin exposure (2, 4, 5, 16, 24), a rate about 10% lower than
that determined for our cohort (35.3%). The higher prevalence of
antecedent vancomycin exposure in our cohort may be a reflec-
tion of variations in local antibiograms or better availability of
data on prior vancomycin exposure. Studies that have attempted
to address the role of prior vancomycin use in reduced vancomy-
cin susceptibility have come to mixed conclusions (25, 26). Inter-
estingly, hVISAmay occur in populations never before exposed to
vancomycin or as a result of exposure to beta-lactam antibiotics
(27, 28). Larger studies are required to better assess the role that
vancomycin plays in selecting for a VISA or hVISA phenotype.
MRSA prediction scores have been previously validated in pa-
tients with pneumonia (29). It was our goal to identify risk factors
for VISA infection in order to help guide empirical therapy in
these patients. Unfortunately, we were unable to find any factors
independently associated with VISA infection.
Interestingly, definitive therapy with linezolid was associated
with an increasedOR formortality in patients with anAPACHE II
score of14. Of the 13 patients who died with linezolid therapy,
10 had an unknown source of infection, 1 had endocarditis, 1 had
FIG 2 Time to appropriate therapy in survivors and nonsurvivors, classified
by MRSA/VISA categorization. MRVISA, methicillin-resistant vancomycin-
intermediate Staphylococcus aureus; VISA, vancomycin-intermediate Staphy-
lococcus aureus.
TABLE 2 Factors associated with 30-day all-cause mortality in




Pneumonia as infectious source 5.08 (1.73–14.87)
Unknown source of infection 5.03 (2.32–10.92)
APACHE II (1-point increments) 1.18 (1.08–1.28)
Solid-organ malignancy 3.16 (1.29–7.72)
Origin: SNF, LTACH, or NH 3.11 (1.13–8.51)
a R-squared value, 0.364. Hosmer-Lemeshow c statistic, 0.958. APACHE II, acute
physiology and chronic health evaluation II; NH, nursing home; SNF, skilled-nursing
facility; LTACH, long-term acute-care hospital.
FIG 3 Kaplan-Meier curve comparing mortality rates of MRSA and VISA
patients. There was no statistically significant difference in mortality (P 
0.231). MRVISA, methicillin-resistant vancomycin-intermediate Staphylococ-
cus aureus; VISA, vancomycin-intermediate Staphylococcus aureus.
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discitis/osteomyelitis, and 1 had pneumonia as the primary source
of infection. None of the patients had catheter-related blood-
stream infection. All 13 patients were bacteremic, 11 with MRSA,
1 withMRVISA, and 1 withMSVISA. None of the patients treated
with linezolid as the definitive therapy had linezolid-resistant S.
aureus isolates. Concerns about increases in mortality with use of
linezolid have been raised before, though in the context of empir-
ical usage in patients with Gram-negative infections (30, 31). The
FDA issued a warning about linezolid in 2007 on the basis of the
aforementioned data (32). In contrast, prior studies have found a
trend not reaching statistical significance toward reduced mortal-
ity in patients treated with linezolid (33). Linezolid as a salvage
therapy for patients with MRSA infections failing vancomycin
therapy has shown success rates superior to and mortality lower
than those seen with vancomycin combination therapy, albeit in a
cohort of only 35 patients (34). Other studies looking at linezolid
as a salvage therapy have shown trends toward improved mortal-
ity that were not statistically significant (35). Clinical responsewas
shown to be superior for linezolid compared to vancomycin for
nosocomial MRSA pneumonia, though there was no difference in
mortality (36). Our results suggest that future studies looking at
linezolid use in a large cohort of patients with high APACHE II
scores are needed to better understand the efficacy of linezolid in
critically ill patients.
One strength of our study is that the presence of VISA was
determined prospectively, which is important as frozen isolates
have been shown to have falsely low vancomycin MICs (37). In
addition to having a high incidence of VISA infections (4% to 6%
of all S. aureus isolates at our institution), we screen forVISAusing
a method that is likely more sensitive and specific than previously
utilized methods (8, 38). Many previous studies have determined
vancomycin MICs retrospectively from stored samples using
VISA detection methods that are less sensitive and less specific
than our own, which could affect conclusions about the relation-
ship between vancomycin MIC and mortality.
The limitations of our study include its retrospective nature, in
which unmeasured confounders could have biased the outcome
measures. This was a single-center study, and results may not be
generalizable to other centers. Due to the limitations of retrospec-
tive chart review, the ability to attain source control could not be
assessed, a data point that could have influenced outcomes. How-
ever, it is standard practice at our institution to remove central
venous catheters if they are felt to be an infectious nidus. Another
limitation is the method of determining 30-day mortality. It is
possible that some patients died outside the BJC HealthCare net-
work and that we were unable to capture their mortality status.
However, it is unlikely that this would have influenced our results
given the almost identical mean times to appropriate therapy for
survivors and nonsurvivors. We were also limited by a lack of
antimicrobial MIC data for MRSA isolates to determine if the
gradation of vancomycin MICs influenced mortality at a cutoff
lower than 4 g/ml. Confirmatory testing for vancomycin MIC
changed over the course of the study, which was another potential
limitation, as different methods are known to produce disparate
MIC results. Vancomycin trough levels were not available for all
patients, which was another limitation of the study, as differences
in target trough attainment could influence outcomes.
In conclusion, VISA infection was not a predictor of mortality,
and neither was time to appropriate antibiotic therapy in theVISA
group. If this finding is reproduced in larger studies, important
implications would include the conclusions that (i) vancomycin
can remain an empirical first-line therapy forMRSAwithout risk-
ing adverse outcomes and (ii) empirical prescription of nonvan-
comycin MRSA therapy in patients with a history of VISA infec-
tionwhen they are readmittedwith concern for infectionwould be
unnecessary, thus preserving nonvancomycin MRSA agents for
use only when necessary. Further studies are required to better
understand the relationship between linezolid usage and outcome
in patients with severe S. aureus infections. More data are needed
to determine risk factors for VISA infection in order to minimize
TABLE 3 Definitive therapy
Patient category (no. of patients)
and antibiotic
No. (%) of patients
Total 30-day mortality
MRVISA (59)a
Daptomycin 33.9 (20) 15 (3)
Ceftaroline 28.8 (17) 5.9 (1)
Linezolid 20.3 (12) 8.3 (1)
Telavancin 11.9 (7) 14.3 (1)
Doxycycline 1.7 (1) 0
Quinupristin-dalfopristin 1.7 (1) 0
Trimethoprim-sulfamethoxazole 1.7 (1) 0
MSVISA (28)
Ceftriaxone 35.7 (10) 0
Cefazolin 25.0 (7) 0
Oxacillin 14.3 (4) 25.0 (1)
Linezolid 7.1 (2) 50.0 (1)
Vancomycin 7.1 (2) 100 (2)
Ceftaroline 3.6 (1) 0
Daptomycin 3.6 (1) 0
Trimethoprim-sulfamethoxazole 3.6 (1) 0
MRSA (267)
Vancomycin 55.1 (147) 15.0 (22)
Ceftaroline 19.9 (53) 15.1 (8)
Daptomycin 12.4 (33) 9.1 (3)
Linezolid 10.9 (29) 37.9 (11)
Doxycycline 1.1 (3) 33.3 (1)
Trimethoprim-sulfamethoxazole 0.4 (1) 0
Telavancin 0.4 (1) 0
a MRVISA, methicillin-resistant vancomycin-intermediate Staphylococcus aureus.
TABLE 4 Factors associated with 30-day all-cause mortality in
multivariate logistic regression analysis, subdivided by sensitivity
analysis category
Sensitivity analysis category and factor
Odds ratio
(95% confidence interval)
Patients with APACHE II 14a
Pneumonia as infectious source 4.23 (1.26–14.25)
Linezolid as definitive therapy 3.26 (1.07–9.9)
Exclusion of patients with central venous
catheter infectionb
Pneumonia as infectious source 4.86 (1.35–17.42)
Unknown source of infection 3.77 (1.41–10.07)
APACHE II (1-point increments) 1.18 (1.07–1.30)
a APACHE II, acute physiology and chronic health evaluation II. R-squared value,
0.237. Hosmer-Lemeshow c statistic, 0.380.
b R-squared value, 0.410. Hosmer-Lemeshow c statistic, 0.770.
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their occurrence, though VISA infections do not appear to be
occurring with a risk of increased mortality at this time. The in-
fluence of a VISA phenotype on the microbiome and in the envi-
ronment is unexplored and could have greater implications than
we recognize at present. As the prevalence of antibiotic resistance
increases, surveillance of drug-resistant pathogens will become
increasingly important and will likely facilitate the collection of
more robust data to understand the complex interaction between
the host, the pathogen, and the antibiotics we use.
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